Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Reckitt to offload Essential Home brands, return $2.2bn to shareholders

(Sharecast News) - Consumer products giant Reckitt Benckiser has announced it is selling off a controlling share in its Essential Home division to private equity firm Advent International in a deal that values the portfolio at $4.8bn. The transaction, which will see Reckitt retain a 30% equity stake in business, will see the company return $2.2bn to shareholders via a special dividend along with a share consolidation upon completion.

Essential Home operates across the air care, surface, pest and laundry segments, known for brands like Air Wick, Calgon and Cillit Bang.

Reckitt says the deal aligns with its strategic plan unveiled last summer to reshape the company into a leading a consumer health and hygiene company focused on a portfolio of 11 high-growth, high-margin so-called "Powerbrands".

The enterprise value of $4.8bn equites to 7.7 times Essential Home's adjusted operating profits for the past fiscal year, and includes up to $1.3bn of contingent and deferred consideration.

Reckitt said it expects to incur cash tax, transaction and other one-off costs relating to the separation of Essential Home of $0.8bn, with the majority payable next year.

However, the company added that it "intends to mitigate the stranded costs from the separation of Essential Home and remains on track to unlock previously communicated cost efficiencies, delivering at least a 300bps reduction in fixed costs and exiting 2027 with a fixed-cost base of c. 19% of net revenue".

Chief executive Kris Licht said the divestment represents a "significant step forward in unlocking the substantial value in our business".

Licht added: "This moves Reckitt towards becoming a simpler, more effective world-class consumer health and hygiene company and it will enable us to focus on a core portfolio of high-growth, high-margin Powerbrands."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.